Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
33.95
+0.10 (0.30%)
At close: Jan 22, 2026, 4:00 PM EST
33.95
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:00 PM EST
Alkermes Revenue
Alkermes had revenue of $390.66M in the quarter ending June 30, 2025, a decrease of -2.12%. This brings the company's revenue in the last twelve months to $1.51B, down -0.17% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.51B
Revenue Growth
-0.17%
P/S Ratio
3.65
Revenue / Employee
$845,188
Employees
1,800
Market Cap
5.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
| Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
| Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
| Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
| Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
| Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
| Dec 31, 2014 | 618.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.59B |
| Dr. Reddy's Laboratories | 3.85B |
| Amneal Pharmaceuticals | 2.93B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
| Indivior | 1.18B |
| Prestige Consumer Healthcare | 1.11B |
| Supernus Pharmaceuticals | 681.54M |
ALKS News
- 9 days ago - Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
- 16 days ago - Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 - Business Wire
- 23 days ago - Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL - PRNewsWire
- 6 weeks ago - Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Alkermes to Participate in Two Upcoming Investor Conferences - Business Wire
- 2 months ago - Alkermes raises offer for Avadel after Lundbeck bid - Reuters